263 related articles for article (PubMed ID: 35658346)
1. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
Zhang H; Sun FH; Chen ZC; Wang Q
Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
[No Abstract] [Full Text] [Related]
2. [Association between the presence of solid or micropapillary components and survival outcome in stage ⅠA lung adenocarcinoma cases: a retrospective cohort study].
Jin KQ; Shen YR; Wu YM; Dai J; Liu XG; Li JQ; Chen LS; Jiang GN
Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):587-592. PubMed ID: 35658347
[No Abstract] [Full Text] [Related]
3. [Analysis of the effect of different pathological subtypes to prognosis in stage I pulmonary adenocarcinoma].
Jiang W; Xi J; Xu S; Lu S; Wang Q
Zhonghua Wai Ke Za Zhi; 2015 Oct; 53(10):737-41. PubMed ID: 26654304
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
6. The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma.
Hou Y; Song W; Chen M; Zhang J; Luo Q; Um SW; Facchinetti F; Bongiolatti S; Zhou Q
Transl Lung Cancer Res; 2022 Jan; 11(1):64-74. PubMed ID: 35242628
[TBL] [Abstract][Full Text] [Related]
7. Micropapillary or solid component predicts worse prognosis in pathological IA stage lung adenocarcinoma: A meta-analysis.
Wang Y; Hu J; Sun Y; Lu Y
Medicine (Baltimore); 2023 Dec; 102(49):e36503. PubMed ID: 38065873
[TBL] [Abstract][Full Text] [Related]
8. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma.
Jeon HW; Kim YD; Sim SB; Moon MH
Thorac Cancer; 2022 Sep; 13(17):2473-2479. PubMed ID: 35820717
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.
Hung JJ; Jeng WJ; Chou TY; Hsu WH; Wu KJ; Huang BS; Wu YC
Ann Surg; 2013 Dec; 258(6):1079-86. PubMed ID: 23532112
[TBL] [Abstract][Full Text] [Related]
12. Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.
Mäkinen JM; Laitakari K; Johnson S; Mäkitaro R; Bloigu R; Lappi-Blanco E; Kaarteenaho R
Lung Cancer; 2015 Dec; 90(3):568-74. PubMed ID: 26506915
[TBL] [Abstract][Full Text] [Related]
13. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
[TBL] [Abstract][Full Text] [Related]
15. The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis-a retrospective study on digitalized slides.
Zombori T; Nyári T; Tiszlavicz L; Pálföldi R; Csada E; Géczi T; Ottlakán A; Pécsy B; Cserni G; Furák J
Virchows Arch; 2018 Jun; 472(6):949-958. PubMed ID: 29611055
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar-predominant lung adenocarcinoma.
Jeon HW; Kim YD; Sim SB; Moon MH
Thorac Cancer; 2021 Jul; 12(14):2072-2077. PubMed ID: 34033216
[TBL] [Abstract][Full Text] [Related]
17. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
[TBL] [Abstract][Full Text] [Related]
18. Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.
Miyoshi T; Aokage K; Katsumata S; Tane K; Ishii G; Tsuboi M
Ann Thorac Surg; 2019 Jul; 108(1):249-255. PubMed ID: 30876742
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
Song W; Hou Y; Zhang J; Zhou Q
Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.
Song Z; Zhu H; Guo Z; Wu W; Sun W; Zhang Y
Eur J Surg Oncol; 2013 Nov; 39(11):1262-8. PubMed ID: 24063970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
